Literature DB >> 24285265

Regulation and activity of secretory leukoprotease inhibitor (SLPI) is altered in smokers.

Megan Meyer1, Rebecca N Bauer, Blanche D Letang, Luisa Brighton, Elizabeth Thompson, Rosalia C M Simmen, James Bonner, Ilona Jaspers.   

Abstract

A hallmark of cigarette smoking is a shift in the protease/antiprotease balance, in favor of protease activity. However, it has recently been shown that smokers have increased expression of a key antiprotease, secretory leukoprotease inhibitor (SLPI), yet the mechanisms involved in SLPI transcriptional regulation and functional activity of SLPI remain unclear. We examined SLPI mRNA and protein secretion in differentiated nasal epithelial cells (NECs) and nasal lavage fluid (NLF) from nonsmokers and smokers and demonstrated that SLPI expression is increased in NECs and NLF from smokers. Transcriptional regulation of SLPI expression was confirmed using SLPI promoter reporter assays followed by chromatin immunoprecipitation. The role of STAT1 in regulating SLPI expression was further elucidated using WT and stat1(-/-) mice. Our data demonstrate that STAT1 regulates SLPI transcription in epithelial cells and slpi protein in the lungs of mice. Additionally, we reveal that NECs from smokers have increased STAT1 mRNA/protein expression. Finally, we demonstrate that SLPI contained in the nasal mucosa of smokers is proteolytically cleaved but retains functional activity against neutrophil elastase. These results demonstrate that smoking enhances expression of SLPI in NECs in vitro and in vivo, and that this response is regulated by STAT1. In addition, despite posttranslational cleavage of SLPI, antiprotease activity against neutrophil elastase is enhanced in smokers. Together, our findings show that SLPI regulation and activity is altered in the nasal mucosa of smokers, which could have broad implications in the context of respiratory inflammation and infection.

Entities:  

Keywords:  antiprotease; cigarette smoking; epithelial cells

Mesh:

Substances:

Year:  2013        PMID: 24285265      PMCID: PMC3920198          DOI: 10.1152/ajplung.00290.2013

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  53 in total

Review 1.  Neutrophils and protease/antiprotease imbalance.

Authors:  R A Stockley
Journal:  Am J Respir Crit Care Med       Date:  1999-11       Impact factor: 21.405

2.  Cathepsin B, L, and S cleave and inactivate secretory leucoprotease inhibitor.

Authors:  C C Taggart; G J Lowe; C M Greene; A T Mulgrew; S J O'Neill; R L Levine; N G McElvaney
Journal:  J Biol Chem       Date:  2001-07-02       Impact factor: 5.157

3.  Noncompetitive enzyme immunoassay for the measurement of bronchial inhibitor in biological fluids.

Authors:  J M Tournier; J Jacquot; P Sadoul; J G Bieth
Journal:  Anal Biochem       Date:  1983-06       Impact factor: 3.365

4.  ELISA for quantitative measurement of low-molecular-weight bronchial protease inhibitor in human sputum.

Authors:  J A Kramps; C Franken; J H Dijkman
Journal:  Am Rev Respir Dis       Date:  1984-06

5.  Comparison of smoker and nonsmoker lavage fluid for the rate of association with neutrophil elastase.

Authors:  M D Wewers; D J Herzyk; J E Gadek
Journal:  Am J Respir Cell Mol Biol       Date:  1989-11       Impact factor: 6.914

6.  Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD.

Authors:  S Gompertz; D L Bayley; S L Hill; R A Stockley
Journal:  Thorax       Date:  2001-01       Impact factor: 9.139

7.  Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells.

Authors:  Suyun Huang; Corazon D Bucana; Melissa Van Arsdall; Isaiah J Fidler
Journal:  Oncogene       Date:  2002-04-11       Impact factor: 9.867

8.  Secretory leucoprotease inhibitor prevents lipopolysaccharide-induced IkappaBalpha degradation without affecting phosphorylation or ubiquitination.

Authors:  Clifford C Taggart; Catherine M Greene; Noel G McElvaney; Shane O'Neill
Journal:  J Biol Chem       Date:  2002-06-25       Impact factor: 5.157

9.  Secretory leucoprotease inhibitor impairs Toll-like receptor 2- and 4-mediated responses in monocytic cells.

Authors:  Catherine M Greene; Noel G McElvaney; Shane J O'Neill; Clifford C Taggart
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

10.  Sulforaphane induces SLPI secretion in the nasal mucosa.

Authors:  Megan Meyer; Matthew J Kesic; John Clarke; Emily Ho; Rosalia C M Simmen; David Diaz-Sanchez; Terry L Noah; Ilona Jaspers
Journal:  Respir Med       Date:  2012-11-26       Impact factor: 3.415

View more
  6 in total

1.  Distribution and factors associated with salivary secretory leukocyte protease inhibitor concentrations.

Authors:  S Rahman; C M Pierce Campbell; B N Torres; M T O'Keefe; D J Ingles; L L Villa; R J Carvalho da Silva; R C Cintra; E Lazcano-Ponce; J Salmeron; M Quiterio; A R Giuliano
Journal:  Oral Dis       Date:  2016-08-17       Impact factor: 3.511

2.  Salivary secretory leukocyte protease inhibitor (SLPI) and head and neck cancer: The Cancer Prevention Study II Nutrition Cohort.

Authors:  Christine M Pierce Campbell; Anna R Giuliano; B Nelson Torres; Michael T O'Keefe; Donna J Ingles; Rebecca L Anderson; Lauren R Teras; Susan M Gapstur
Journal:  Oral Oncol       Date:  2016-02-24       Impact factor: 5.337

Review 3.  Respiratory protease/antiprotease balance determines susceptibility to viral infection and can be modified by nutritional antioxidants.

Authors:  Megan Meyer; Ilona Jaspers
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-04-17       Impact factor: 5.464

4.  Tonsillar swabs and sputum predict SLPI- and AnxA2 expression in tonsils: A prospective study on smoking dependent SLPI- and AnxA2-expression, and tonsillar HPV infection.

Authors:  Elgar Susanne Quabius; Alessa Heinrichs; André Kühnel; Martin Laudien; Florian Hoppe; Robert Mlynski; Petra Ambrosch; Markus Hoffmann
Journal:  Oncol Lett       Date:  2022-03-28       Impact factor: 2.967

5.  Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations.

Authors:  Aran Singanayagam; Nicholas Glanville; Jason L Girkin; Yee Man Ching; Andrea Marcellini; James D Porter; Marie Toussaint; Ross P Walton; Lydia J Finney; Julia Aniscenko; Jie Zhu; Maria-Belen Trujillo-Torralbo; Maria Adelaide Calderazzo; Chris Grainge; Su-Ling Loo; Punnam Chander Veerati; Prabuddha S Pathinayake; Kristy S Nichol; Andrew T Reid; Phillip L James; Roberto Solari; Peter A B Wark; Darryl A Knight; Miriam F Moffatt; William O Cookson; Michael R Edwards; Patrick Mallia; Nathan W Bartlett; Sebastian L Johnston
Journal:  Nat Commun       Date:  2018-06-08       Impact factor: 14.919

Review 6.  Epithelial Barrier Dysfunction in Chronic Respiratory Diseases.

Authors:  François M Carlier; Charlotte de Fays; Charles Pilette
Journal:  Front Physiol       Date:  2021-06-24       Impact factor: 4.566

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.